Enveric Biosciences, Inc.: Form 10-K/A for the period ended Dec 31, 2016
Filed with the SEC on Apr 4, 2017 and accepted by EDGAR at Apr 3, 2017, 20:18 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2016-01-01 to 2016-12-31 | $36.1m | us-gaap:Revenues |
| Cost of revenue | 12 months2016-01-01 to 2016-12-31 | $29.6m | us-gaap:CostOfRevenue |
| Gross profit | 12 months2016-01-01 to 2016-12-31 | $6.5m | us-gaap:GrossProfit |
| Research and development | 12 months2016-01-01 to 2016-12-31 | $55.1k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2016-01-01 to 2016-12-31 | −$5.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2016-01-01 to 2016-12-31 | $751.1k | us-gaap:InterestExpense |
| Income tax | 12 months2016-01-01 to 2016-12-31 | −$3.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2016-01-01 to 2016-12-31 | −$2.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2016-01-01 to 2016-12-31 | −$0.21 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2016-01-01 to 2016-12-31 | −$0.21 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2016-01-01 to 2016-12-31 | 13,068,597 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2016-01-01 to 2016-12-31 | −$2.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2016-12-31 | $1.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-12-31 | $10.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2016-12-31 | $39.5m | us-gaap:Assets |
| Current liabilities | At period end2016-12-31 | $12.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-12-31 | $27.8m | us-gaap:Liabilities |
| Long-term debt | At period end2016-12-31 | $405.4k | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2016-12-31 | $1.5m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2016-12-31 | $11.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001079974-17-000131. Last ingested by Listed: Nov 14, 2026, 20:02 ET. Listed shows no prices and gives no investment advice.